Stefanie Lerche1,2, Claudia Schulte1,2, Karin Srulijes1,2, Andrea Pilotto1,3, Tim W Rattay1,2, Ann-Kathrin Hauser1,2, Elke Stransky1, Christian Deuschle1,2, Ilona Csoti4, Ingolf Lachmann5, Henrik Zetterberg6,7,8, Inga Liepelt-Scarfone1,2, Thomas Gasser1,2, Walter Maetzler1,2,9, Daniela Berg1,2,9, Kathrin Brockmann1,2. 1. Center of Neurology, Department of Neurodegeneration and Hertie-Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany. 2. German Center for Neurodegenerative Diseases, University of Tuebingen, Tuebingen, Germany. 3. Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy. 4. Gertrudis Klinik, Parkinson-Center, Leun-Biskirchen, Germany. 5. AJ Roboscreen GmbH, Leipzig, Germany. 6. Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden. 7. Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden. 8. Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK. 9. Department of Neurology, Christian-Albrechts University, Kiel, Germany.
Abstract
BACKGROUND: A proportion of idiopathic Parkinson's disease patients (PDidiopathic ) with dementia show altered CSF profiles of amyloid β (Aβ) and Tau. PD patients with Glucocerebrosidase (GBA) mutations (PDGBA ) present with even more cognitive decline than seen in PDidiopathic . OBJECTIVE: The objective of this study was to evaluate whether CSF profiles of Aβ and tau are associated with the prominent cognitive impairment in PDGBA . METHODS: CSF levels of Aβ1-42 , t-Tau, p-Tau, and total alpha-synuclein were assessed in 479 participants (50 PDGBA , 308 PDidiopathic , 121 healthy controls). RESULTS: Older age was associated with cognitive impairment in PDGBA and PDidiopathic . Despite prominent cognitive impairment, PDGBA showed similar CSF levels of Aβ1-42 , t-Tau, and p-Tau as seen in healthy controls. In contrast, lower levels of Aβ1-42 and higher levels of t-Tau and p-Tau were associated with worse cognitive performance in PDidiopathic . CONCLUSIONS: The prominent cognitive impairment in PDGBA seems not primarily associated with Aβ and Tau profiles in CSF.
BACKGROUND: A proportion of idiopathic Parkinson's diseasepatients (PDidiopathic ) with dementia show altered CSF profiles of amyloid β (Aβ) and Tau. PDpatients with Glucocerebrosidase (GBA) mutations (PDGBA ) present with even more cognitive decline than seen in PDidiopathic . OBJECTIVE: The objective of this study was to evaluate whether CSF profiles of Aβ and tau are associated with the prominent cognitive impairment in PDGBA . METHODS: CSF levels of Aβ1-42 , t-Tau, p-Tau, and total alpha-synuclein were assessed in 479 participants (50 PDGBA , 308 PDidiopathic , 121 healthy controls). RESULTS: Older age was associated with cognitive impairment in PDGBA and PDidiopathic . Despite prominent cognitive impairment, PDGBA showed similar CSF levels of Aβ1-42 , t-Tau, and p-Tau as seen in healthy controls. In contrast, lower levels of Aβ1-42 and higher levels of t-Tau and p-Tau were associated with worse cognitive performance in PDidiopathic . CONCLUSIONS: The prominent cognitive impairment in PDGBA seems not primarily associated with Aβ and Tau profiles in CSF.
Authors: Roy N Alcalay; Victoria Mallett; Benoît Vanderperre; Omid Tavassoly; Yves Dauvilliers; Richard Y J Wu; Jennifer A Ruskey; Claire S Leblond; Amirthagowri Ambalavanan; Sandra B Laurent; Dan Spiegelman; Alexandre Dionne-Laporte; Christopher Liong; Oren A Levy; Stanley Fahn; Cheryl Waters; Sheng-Han Kuo; Wendy K Chung; Blair Ford; Karen S Marder; Un Jung Kang; Sharon Hassin-Baer; Lior Greenbaum; Jean-Francois Trempe; Pavlina Wolf; Petra Oliva; Xiaokui Kate Zhang; Lorraine N Clark; Melanie Langlois; Patrick A Dion; Edward A Fon; Nicolas Dupre; Guy A Rouleau; Ziv Gan-Or Journal: Mov Disord Date: 2019-02-20 Impact factor: 10.338
Authors: Tanya Simuni; Liz Uribe; Hyunkeun Ryan Cho; Chelsea Caspell-Garcia; Christopher S Coffey; Andrew Siderowf; John Q Trojanowski; Leslie M Shaw; John Seibyl; Andrew Singleton; Arthur W Toga; Doug Galasko; Tatiana Foroud; Duygu Tosun; Kathleen Poston; Daniel Weintraub; Brit Mollenhauer; Caroline M Tanner; Karl Kieburtz; Lana M Chahine; Alyssa Reimer; Samantha J Hutten; Susan Bressman; Kenneth Marek Journal: Lancet Neurol Date: 2019-10-31 Impact factor: 44.182
Authors: Tanya Simuni; Michael C Brumm; Liz Uribe; Chelsea Caspell-Garcia; Christopher S Coffey; Andrew Siderowf; Roy N Alcalay; John Q Trojanowski; Leslie M Shaw; John Seibyl; Andrew Singleton; Arthur W Toga; Doug Galasko; Tatiana Foroud; Kelly Nudelman; Duygu Tosun-Turgut; Kathleen Poston; Daniel Weintraub; Brit Mollenhauer; Caroline M Tanner; Karl Kieburtz; Lana M Chahine; Alyssa Reimer; Samantha Hutten; Susan Bressman; Kenneth Marek Journal: Mov Disord Date: 2020-02-19 Impact factor: 10.338